Sign In
Buy DYN
$17.99
+0.750 (+4.35%)
At Close: Jun 03, 2026
Dyne Therapeutics: 2026 Catalysts Point To Further Upside
04:07am, Tuesday, 27'th Jan 2026
Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases with two lead clinical programs approaching pivotal milestones. DYNE-101 shows strong safety and functional
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
07:30am, Tuesday, 20'th Jan 2026
- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEV
Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN
04:31am, Tuesday, 20'th Jan 2026
Campbell and CO Investment Adviser LLC bought a new stake in Dyne Therapeutics, Inc. (NASDAQ: DYN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commis
Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
11:05pm, Wednesday, 14'th Jan 2026
Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 07'th Jan 2026
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
07:30am, Tuesday, 23'rd Dec 2025
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of “Moderate Buy” by Analysts
01:46am, Monday, 15'th Dec 2025
Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nineteen analysts that are covering the company, Marketbeat.com reports. One equi
WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday
06:00pm, Wednesday, 10'th Dec 2025
An analyst upgraded his recommendation on the biotech. He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target.
Dyne Therapeutics: Why The $350M Public Offering Was Critical
11:36am, Wednesday, 10'th Dec 2025
Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one y
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
09:42pm, Tuesday, 09'th Dec 2025
WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Why Dyne Therapeutics Stock Tanked on Tuesday
06:22pm, Tuesday, 09'th Dec 2025
The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares.
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
06:00am, Tuesday, 09'th Dec 2025
Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
04:02pm, Monday, 08'th Dec 2025
WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Why Dyne Therapeutics Stock Was Blasting Higher Today
02:47pm, Monday, 08'th Dec 2025
Its No. 1 drug candidate did well in a clinical trial. It met both its primary and secondary endpoints.
